Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,127 public posts
Filter results
Rucaparib in Metastatic Castration-Resistant Prostate Cancer With BRCA1/2 Alteration
BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration
-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors.
BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration
-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Rising Psa
Does that make me
castration
resistant? Also what questions should I ask my MO? By the way, thanks to all who post here, this is such a great site full of information and compassion.Thanks and good luck to all of us. Steve
Does that make me
castration
resistant? Also what questions should I ask my MO? By the way, thanks to all who post here, this is such a great site full of information and compassion.Thanks and good luck to all of us. Steve
thesteve
in
Advanced Prostate Cancer
4 years ago
My dad has advanced cancer
Oncologists no, that the psa should have dropped to 0 and that it is at 2 means that "the blockade is not working and the cancer already shows that it is resistant to
castration
". A group of oncologists propose to start chemotherapy with Docetaxel and others Abiratirone.
Oncologists no, that the psa should have dropped to 0 and that it is at 2 means that "the blockade is not working and the cancer already shows that it is resistant to
castration
". A group of oncologists propose to start chemotherapy with Docetaxel and others Abiratirone.
azulmsalas
in
Advanced Prostate Cancer
4 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Relugolix versus Leuprolide - Neal Shore video.
Of men who received relugolix, 96.7% (95% confidence interval [CI], 94.9 to 97.9) maintained
castration
through 48 weeks, as compared with 88.8% (95% CI, 84.6 to 91.8) of men receiving leuprolide.
Of men who received relugolix, 96.7% (95% confidence interval [CI], 94.9 to 97.9) maintained
castration
through 48 weeks, as compared with 88.8% (95% CI, 84.6 to 91.8) of men receiving leuprolide.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Thymus
"The atrophy is due to the increased circulating level of sex hormones, and chemical or physical
castration
of an adult results in the thymus increasing in size and activity."" [3] From today's New York Times "
How the Coronavirus Short-Circuits the Immune System
" by Gina Kolata [4]: "Children
"The atrophy is due to the increased circulating level of sex hormones, and chemical or physical
castration
of an adult results in the thymus increasing in size and activity."" [3] From today's New York Times "
How the Coronavirus Short-Circuits the Immune System
" by Gina Kolata [4]: "Children
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Castration resistance
Just curious what other
castration
resistant prostate cancer warriors out there are doing?
Just curious what other
castration
resistant prostate cancer warriors out there are doing?
Cleodman
in
Advanced Prostate Cancer
4 years ago
New Clinical Trial. Clinical trial evaluates radiopharmaceutical as therapy for biochemically recurrent prostate cancer
cid=eb_govdel https://clinicaltrials.gov/ct2/show/NCT04206319 Xofigo is radium 223 but Xofigo is indicated and approved for the treatment of patients with
castration
-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease..
cid=eb_govdel https://clinicaltrials.gov/ct2/show/NCT04206319 Xofigo is radium 223 but Xofigo is indicated and approved for the treatment of patients with
castration
-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease..
tango65
in
Advanced Prostate Cancer
4 years ago
Lupron fatigue, etc.
I am accepting the reality of what seems like
castration
, hot flashes, sudden increase of love handles, increase of incontinence, too many early morning trips to bathroom, and occasional diarrhea, presumably par for the course.
I am accepting the reality of what seems like
castration
, hot flashes, sudden increase of love handles, increase of incontinence, too many early morning trips to bathroom, and occasional diarrhea, presumably par for the course.
nexusprom
in
Advanced Prostate Cancer
4 years ago
Bipolar Androgen Therapy in Prostate Cancer.
I can't readily access the review itself, but I liked that the authors explain the rationale for BAT more clearly than I may have done in the past: "New-generation hormone therapies improved overall survival in
castration
-resistant prostate cancer.
I can't readily access the review itself, but I liked that the authors explain the rationale for BAT more clearly than I may have done in the past: "New-generation hormone therapies improved overall survival in
castration
-resistant prostate cancer.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Next treatment step for mCRPC and urinary retention
My father has been resistant to
castration
(mCRPC). His PSA (May 2020) is 5.683 ng/ml with new left pelvis and inguinal lymph nodes. I read articles of treatment steps on HeathUnlocked and understand that chemotherapy should be taken before zytiga, shouldn’t it?
My father has been resistant to
castration
(mCRPC). His PSA (May 2020) is 5.683 ng/ml with new left pelvis and inguinal lymph nodes. I read articles of treatment steps on HeathUnlocked and understand that chemotherapy should be taken before zytiga, shouldn’t it?
Hidden
in
Advanced Prostate Cancer
4 years ago
Abiraterone [Zytiga] or Enzalutamide [Xtandi]?
" [2] *** "
Background:
Abiraterone and enzalutamide may increase the risk of cardiovascular events in patients with
castration
-resistant prostate cancer (CRPC).
" [2] *** "
Background:
Abiraterone and enzalutamide may increase the risk of cardiovascular events in patients with
castration
-resistant prostate cancer (CRPC).
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Folate consumption & ADT mortality.
In parallel, we tested
castration
of C57BL/6J mice on folate-defined diet to determine if folate levels change with response to androgen deprivation.
In parallel, we tested
castration
of C57BL/6J mice on folate-defined diet to determine if folate levels change with response to androgen deprivation.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Free vs Total Testosterone? - Redux.
One possible incentive for the continuation of conventional ADT may lay in the assumption of a broader mode of therapy in the
castration
-resistant state. The mechanisms that lead to the
castration
-resistant state are numerous and have been subjected to extensive research in the past.
One possible incentive for the continuation of conventional ADT may lay in the assumption of a broader mode of therapy in the
castration
-resistant state. The mechanisms that lead to the
castration
-resistant state are numerous and have been subjected to extensive research in the past.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
PARP Inhibitors for Metastatic Castration-Resistant Prostate CancerInterview with Oliver Sartor MD
This study did not require chemotherapy but did require use of a novel hormone, either in the hormone-sensitive or
castration
-resistant space. All the patients, in essence, were pretreated with abiraterone and enzalutamide, and they may or may not have been pretreated for docetaxel.
This study did not require chemotherapy but did require use of a novel hormone, either in the hormone-sensitive or
castration
-resistant space. All the patients, in essence, were pretreated with abiraterone and enzalutamide, and they may or may not have been pretreated for docetaxel.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer The New England Journal of Medicine
Of men who received relugolix, 96.7% (95% confidence interval [CI], 94.9 to 97.9) maintained
castration
through 48 weeks, as compared with 88.8% (95% CI, 84.6 to 91.8) of men receiving leuprolide.
Of men who received relugolix, 96.7% (95% confidence interval [CI], 94.9 to 97.9) maintained
castration
through 48 weeks, as compared with 88.8% (95% CI, 84.6 to 91.8) of men receiving leuprolide.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Metastasis-Directed Therapy in Oligoprogressive Castration-Resistant Prostate Cancer
TAKE-HOME MESSAGE •This retrospective study reports the clinical outcomes of patients with
castration
-resistant prostate cancer treated with metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy.
TAKE-HOME MESSAGE •This retrospective study reports the clinical outcomes of patients with
castration
-resistant prostate cancer treated with metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Dad has Stage 4 Prostate Cancer; rising PSA levels?
I also understand that it isn't necessarily the end of the world, as chemo/radiation are still options, but I'm wondering if the aforementioned spikes in my Dad's PSA is indicative of his cancer being/becoming
castration
-resistant? Or is this just his cancer rising a bit before it stabilizes again?
I also understand that it isn't necessarily the end of the world, as chemo/radiation are still options, but I'm wondering if the aforementioned spikes in my Dad's PSA is indicative of his cancer being/becoming
castration
-resistant? Or is this just his cancer rising a bit before it stabilizes again?
bern5
in
Advanced Prostate Cancer
4 years ago
High Testosterone after one month Leuprolide shot
How long is supposed to take to get
castration
levels?
How long is supposed to take to get
castration
levels?
olloreda
in
Advanced Prostate Cancer
4 years ago
Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer MedPage Today Commentary - 07/08/2020
Morgans is a regular contributor at the fine URO Today website (https://www.urotoday.com/center-of-excellence/advanced-prostate-cancer.html)[/i]
Alicia Morgans, MD, on Treatment Options for Metastatic
-Sensitive Prostate Cancer https://www.medpagetoday.com/reading-room/asco/non-prostate-genitourinary-cancer
Morgans is a regular contributor at the fine URO Today website (https://www.urotoday.com/center-of-excellence/advanced-prostate-cancer.html)[/i]
Alicia Morgans, MD, on Treatment Options for Metastatic
-Sensitive Prostate Cancer https://www.medpagetoday.com/reading-room/asco/non-prostate-genitourinary-cancer
cujoe
in
Fight Prostate Cancer
4 years ago
SPARTAN - Overall Survival.
Patient summary With data presented herein, all primary and secondary study end points of SPARTAN were met; findings demonstrate the value of apalutamide as a treatment option for nonmetastatic
castration
-resistant prostate cancer. *** click on link for full text.
Patient summary With data presented herein, all primary and secondary study end points of SPARTAN were met; findings demonstrate the value of apalutamide as a treatment option for nonmetastatic
castration
-resistant prostate cancer. *** click on link for full text.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
1
...
28
29
30
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1004 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest